Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (159 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 14.3% (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: infantsthe purposepurpose ofmultiplevitamin
  Phrases that lowered it: comparegoodhealthbased onblood
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 8.7% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 18 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 68.8% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 18304 (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 3791 (raises risk) · Drug's FDA history
• Maximum age: 45 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pregnancy Outcome and Vitamin D Level Among Vitamin D Supplementation During Pregnancy NCT04591847 · started 2020 · scored riskier than 6% of active trials completed
• Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation NCT01932788 · started 2013 · scored riskier than 8% of active trials completed
• Effect of Vitamin D3 Supplementation in Pregnancy on Risk of Pre-eclampsia NCT03101150 · started 2012 · scored riskier than 6% of active trials completed
• Vitamin D3 Treatment and Homocysteine Concentrations Among Overweight Reproductive Women NCT03310307 · started 2016 · scored riskier than 7% of active trials completed
• Vitamin D Supplementation to Prevent Vitamin D Deficiency for Children With Epilepsy NCT03536845 · started 2018 · scored riskier than 16% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.